People discharged from the hospital with MS are 30% less likely to have had a myocardial infarction and 58% less likely to have ischemic heart disease.
In the course of a 24-week cessation of treatment with the humanized monoclonal antibody, natalizumab, in patients with RRMS, pharmacokinetic, pharmacodynamic, and serum immune parameters normalized by 4 months.
The oral disease-modifying drug under development for the treatment of relapsing-remitting multiple sclerosis, teriflunomide, was not superior to interferon beta-1a in risk of treatment failure.
The monoclonal antibody, alemtuzumab, significantly reducesthe number of relapses and the accumulation of disability in patients with relapsing-remitting multiple sclerosis who had relapsed on prior therapy.
After a 24-week cessation of natalizumab treatment, a high rate of MRI and clinical disease activity recurs in patients with multiple sclerosis.
Treatment with the investigational oral treatment for relapsing-remitting multiple sclerosis, dimethyl fumarate (aka BG-12), yielded significant reductions in the annualized relapse rate and risk of relapse.
Treatment with the investigational oral drug for RRMS, dimethylfumarate (aka BG-12), yielded significant reductions in inflammatory disease activity using MRI outcomes.
The once-daily oral MS drug, fingolimod, reduces annualized relapse rates in patients who achieved unsatisfactory responses when treated with other disease-modifying therapies or who had been treated for an extended period of time.
The once-daily oral MS drug, fingolimod, slows brain volume loss in patients with MS, regardless of inflammatory activity.
In clinical trials, treatment of patients with the oral disease-modifying therapy, teriflunomide, for relapsing forms of multiple sclerosis can result in hair loss/thinning, but this side effect is generally manageable.
People with MS frequently reported having both episodic and chronic migraines, with Hispanic MS patients experiencing significantly more chronic migraines.
Cholestyramine and activated charcoal can be used to virtually eliminate the long half-life oral investigational multiple sclerosis drug, teriflunomide, from the plasma in 11 days.
HCPLive will be providing live coverage from the 2012 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting in cooperation with Americans Committe for Treatment and Research in Multiple Sclerosis (ACTRIMS). Here are some of the highlights to look forward to during the meeting.
This year's Constorium of Multiple Sclerosis Centers Annual Meeting is being hosted in San Diego known for its fresh seafood and wines. Here are some recommendations of restaurants to dine-in.
Patients with MS and their physicians have long been aware that the risk of acquiring the disease is higher when there is a history of MS in the family.
Those who treat autoimmune diseases such as MS, much has been expected from stem cell research, and an ongoing study at the University of Cambridge, UK, has become a focus of high hopes.
Dr. John R. Rinker, II Assistant Professor of Neurology Outlines some highlights of his study The Nature of MS: Epidemiology, Diagnosis, Natural History and Clinical Course.
